University College, London: Lymphoma trials

The registry lists 22 Lymphoma studies with University College, London as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 14Phase 3 5No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell LymphomaRecruitingNCT06071871Phase 2
• Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell LymphomaRecruitingNCT05635162Phase 2
• Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphomaNot yet recruitingNCT05627115Phase 2
• Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ MalignanciesRecruitingNCT05391490Phase 1
• A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT03873025Phase 1/2
• Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window StudyActive, not recruitingNCT03617666Phase 2
• A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)Active, not recruitingNCT03385226Phase 2
• ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT03337919Phase 2
• Whole Body PET-MRI in Paediatric and Adolescent LymphomaStatus unknownNCT02935348
• Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19Active, not recruitingNCT02935257Phase 1
• Trial of Haploidentical Stem Cell Transplantation for Haematological CancersCompletedNCT01597219Phase 2
• MELT - MRI Evaluation of Lymphoma TreatmentCompletedNCT01459224
• Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological CancersStatus unknownNCT01240525Phase 2
• Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaCompletedNCT00971763Phase 2
• PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin LymphomaActive, not recruitingNCT00943423Phase 3
• Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System LymphomaCompletedNCT00727831Phase 1/2
• Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin LymphomaCompletedNCT00678327Phase 3
• Combination Chemotherapy in Treating Younger Patients With Hodgkin LymphomaCompletedNCT00666484Phase 2
• Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin LymphomaCompletedNCT00660231Phase 2
• Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell LymphomaCompletedNCT00641095Phase 2/3
• Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's LymphomaCompletedNCT00310167Phase 3
• Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaCompletedNCT00112931Phase 3